WEKO3
アイテム
Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma
https://repo.qst.go.jp/records/49516
https://repo.qst.go.jp/records/49516cb17a8ea-96c9-4d40-ac9b-73ba7dd8a4e8
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-12-28 | |||||
| タイトル | ||||||
| タイトル | Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kasuya, Goro
× Kasuya, Goro× Tsuji, Hiroshi× Nomiya, Takuma× Makishima, Hirokazu× Haruyama, Yasuo× Kobashi, Gen× Hayashi, Kazuhiko× Ebner, Daniel× Omatsu, Tokuhiko× Kishimoto, Riwa× Yasuda, Shigeo× Igarashi, Tatsuo× Oya, Mototsugu× Akakura, Koichiro× Suzuki, Hiroyoshi× Ichikawa, Tomohiko× Shimazaki, Jun× Kamada, Tadashi× Group for Genitourinary Tumors, Working× Kasuya, Goro× Tsuji, Hiroshi× Nomiya, Takuma× Makishima, Hirokazu× Ebner, Daniel× Omatsu, Tokuhiko× Kishimoto, Riwa× Yasuda, Shigeo× Kamada, Tadashi |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The aims of this study were to clarify the safety and efficacy of 12-fraction carbon-ion radiotherapy (CIRT) for primary renal cell carcinoma (RCC) and to confirm the recommended dose in a prospective clinical trial. This clinical trial was planned as a non-randomized, open-label, single-center phase I/II study of CIRT monotherapy. The incidence of acute adverse events was the primary endpoint. Dose-limiting toxicities (DLTs) were defined as grade ≥3 skin, gastrointestinal tract, or urologic adverse events. Based on the eligibility criteria, 8 patients with primary RCC, including 3 medically inoperable patients and 5 patients with tumors >4 cm, were enrolled. Of the 8 patients, 5 were treated with 66 Gy (relative biological effectiveness [RBE]), and subsequently, the dose was escalated to 72 Gy (RBE) for the remaining 3 patients. The median follow-up time was 43.1 months. No DLTs were observed at any dose level though the end of follow-up. Although 1 patient died of pneumonia 3 months after CIRT, which was determined to be unrelated to CIRT, no grade 3 or higher adverse events were observed, and both local control and cancer-specific survival rates were 100%. In conclusion, the safety and efficacy of CIRT hypofractionation using 12-fractions for the treatment of eligible RCC patients, including those with inoperable or tumor size >4 cm, were confirmed in this prospective trial, and a recommended dose of 72 Gy (RBE) was established. |
|||||
| 書誌情報 |
Oncotarget 巻 10, 号 1, p. 76-81, 発行日 2019-01 |
|||||
| 出版者 | ||||||
| 出版者 | Inpact Journals | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1949-2553 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.18632/oncotarget.26539 | |||||
